Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antipsychotic_medication
|
| gptkbp:approvalYear |
1997
|
| gptkbp:ATCCode |
N05AH04
|
| gptkbp:brand |
gptkb:Seroquel_XR
Ketipinor Quetidin Qutan |
| gptkbp:chemicalFormula |
C21H25N3O2S
|
| gptkbp:contraindication |
hypersensitivity to quetiapine
|
| gptkbp:drugClass |
gptkb:antipsychotic_medication
|
| gptkbp:eliminationHalfLife |
about 6 hours
|
| gptkbp:firstMarketedYear |
1997
|
| gptkbp:form |
immediate release
extended release |
| gptkbp:genericAvailable |
yes
|
| gptkbp:genericName |
gptkb:quetiapine
|
| gptkbp:interactsWith |
CYP3A4 inhibitors
CYP3A4 inducers central nervous system depressants antihypertensive drugs |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:marketedAs |
gptkb:United_States
|
| gptkbp:mechanismOfAction |
antagonist at histamine H1 receptors
antagonist at adrenergic alpha1 receptors antagonist at muscarinic receptors antagonist at serotonin 5-HT2A and dopamine D2 receptors |
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:overdoseSymptoms |
hypotension
tachycardia somnolence coma (rare) |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionRequired |
yes
|
| gptkbp:riskFactor |
neuroleptic malignant syndrome
tardive dyskinesia suicidal thoughts (in young people) increased mortality in elderly with dementia-related psychosis |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:orthostatic_hypotension
constipation dizziness fatigue weight gain drowsiness dry mouth increased appetite extrapyramidal symptoms (rare) elevated blood sugar |
| gptkbp:storage |
room temperature
|
| gptkbp:tabletColor |
varies by strength (white, yellow, peach, etc.)
|
| gptkbp:usedFor |
bipolar disorder
schizophrenia major depressive disorder (adjunct) |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:quetiapine
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Seroquel
|